secwatch.observer — SEC 8-K summary
======================================

Issuer:     LeonaBio, Inc. (LONA)
CIK:        0001620463
Form:       8-K
Filed at:   2022-03-21T23:59:59+00:00
Accession:  0001193125-22-080027
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Athira Pharma appoints Dr. Michael Panzara to board effective March 18, 2022
----------------------------------------------------------------------------

- Dr. Panzara, CMO at Wave Life Sciences, appointed Class I director with term expiring at 2024 annual meeting.
- He brings over 20 years CNS drug development experience, including leadership at Sanofi Genzyme and Biogen.
- Compensation includes initial stock option grant; no transactions with the company or its affiliates.
- Press release notes his role in global regulatory approvals of MS drugs LEMTRADA, AUBAGIO, and TYSABRI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/0001193125-22-080027-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1620463/000119312522080027/d277480d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-080027

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer